On possible practical applications of the gut microbiome research in the prevention, diagnosis, assessment of, and treatment modification for multiple sclerosis in patients from risk groups

View or download the full article: 
PDF icon health-risk-analysis-2023-3-14.pdf
UDC: 
616-009
DOI: 
10.21668/health.risk/2023.3.14.eng
Authors: 

C.K. Zjukovskaja

Organization: 

Rencontres Internationales Santé Environnement – RISE, Strasbourg, France

Abstract: 

Research into the gut microbiota (GM) in multiple sclerosis (MS) has the potential to lead to a number of practical applications in the prevention, diagnosis, assessment of, and treatment modification for, MS. Four most promising areas include biomarkers, treatment personalization, drug development as well as disease prevention and mitigation.

Changes in the GM have been observed in individuals with MS; analysis of the GM composition may help to identify individuals at risk of developing the disease or to monitor disease progression. Dietary interventions aimed at improving gut health could be used as a complementary approach to traditional MS treatments in order to reduce inflammation thereby potentially improving MS symptoms and lessening disease progression. Differences in the GM between individuals with MS suggest that personalized treatment approaches based on an individual's microbiome composition could be effective. Manipulating the GM could therefore be a potential avenue for drug development in MS. In addition, the exploration of bacteria or bacterial metabolites as therapeutic agents to modulate the immune system and reduce inflammation is also promising.

Such explorations may even help identify strategies for preventing the development of MS in at-risk individuals. Overall, practical applications of gut microbiome research in MS are still in the early stages and further research is needed to fully understand the mechanisms underlying the relationship between the gut microbiome and MS and to determine the most effective interventions for improving gut health in individuals with the disease.

Keywords: 
multiple sclerosis, gut microbiome, prevention, diagnostics, treatment personalization, biomarkers, risk of a disease, diet
Zjukovskaja C.K. On possible practical applications of the gut microbiome research in the prevention, diagnosis, assess-ment of, and treatment modification for multiple sclerosis in patients from risk groups. Health Risk Analysis, 2023, no. 3, pp. 136–141. DOI: 10.21668/health.risk/2023.3.14.eng
References: 
  1. GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol., 2019, vol. 18, no. 3, pp. 269–285. DOI: 10.1016/s1474-4422(18)30443-5
  2. iMSMS Consortium. Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course. Cell, 2022, vol. 185, no. 19, pp. 3467–3486.e16. DOI: 10.1016/j.cell.2022.08.021
  3. Ferri C., Castellazzi M., Merli N., Laudisi M., Baldin E., Baldi E., Mancabelli L., Ventura M., Pugliatti M. Gut Microbiota Changes during Dimethyl Fumarate Treatment in Patients with Multiple Sclerosis. Int. J. Mol. Sci., 2023, vol. 24, no. 3, pp. 2720. DOI: 10.3390/ijms24032720
  4. Pilotto S., Zoledziewska M., Fenu G., Cocco E., Lorefice L. Disease-modifying therapy for multiple sclerosis: Implications for gut microbiota. Mult. Scler. Relat. Disord., 2023, vol. 73, pp. 104671. DOI: 10.1016/j.msard.2023.104671
  5. Kurowska A., Ziemichód W., Herbet M., Piątkowska-Chmiel I. The Role of Diet as a Modulator of the Inflammatory Process in the Neurological Diseases. Nutrients, 2023, vol. 15, no. 6, pp. 1436. DOI: 10.3390/nu15061436
  6. Bock M., Steffen F., Zipp F., Bittner S. Impact of Dietary Intervention on Serum Neurofilament Light Chain in Multiple Sclerosis. Neurol. Neuroimmunol. Neuroinflamm., 2021, vol. 9, no. 1, pp. e1102. DOI: 10.1212/nxi.0000000000001102
  7. Jiang Z., Yin X., Wang M., Chen T., Wang Y., Gao Z., Wang Z. Effects of Ketogenic Diet on Neuroinflammation in Neurodegenerative Diseases. Aging Dis., 2022, vol. 13, no. 4, pp. 1146–1165. DOI: 10.14336/ad.2021.1217
  8. Rahimlou M., Nematollahi S., Husain D., Banaei-Jahromi N., Majdinasab N., Hosseini S.A. Probiotic supplementation and systemic inflammation in relapsing-remitting multiple sclerosis: A randomized, double-blind, placebo-controlled trial. Front. Neurosci., 2022, vol. 16, pp. 901846. DOI: 10.3389/fnins.2022.901846
  9. Dziedzic A., Saluk J. Probiotics and Commensal Gut Microbiota as the Effective Alternative Therapy for Multiple Sclerosis Patients Treatment. Int. J. Mol. Sci., 2022, vol. 23, no. 22, pp. 14478. DOI: 10.3390/ijms232214478
  10. Correale J., Hohlfeld R., Baranzini S.E. The role of the gut microbiota in multiple sclerosis. Nat. Rev. Neurol., 2022, vol. 18, no. 9, pp. 544–558. DOI: 10.1038/s41582-022-00697-8
  11. Christovich A., Luo X.M. Gut Microbiota, Leaky Gut, and Autoimmune Diseases. Front. Immunol., 2022, vol. 13, pp. 946248. DOI: 10.3389/fimmu.2022.946248
  12. Al K.F., Craven L.J., Gibbons S., Parvathy S.N., Wing A.C., Graf C., Parham K.A., Kerfoot S.M. [et al.]. Fecal microbiota transplantation is safe and tolerable in patients with multiple sclerosis: A pilot randomized controlled trial. Mult. Scler. J. Exp. Transl. Clin., 2022, vol. 8, no. 2, pp. 20552173221086662. DOI: 10.1177/20552173221086662
  13. Matheson J.-A.T., Holsinger R.M.D. The Role of Fecal Microbiota Transplantation in the Treatment of Neurodegenerative Diseases: A Review. Int. J. Mol. Sci., 2023, vol. 24, no. 2, pp. 1001. DOI: 10.3390/ijms24021001
  14. Shahi S.K., Ghimire S., Lehman P., Mangalam A.K. Obesity induced gut dysbiosis contributes to disease severity in an animal model of multiple sclerosis. Front. Immunol., 2022, vol. 13, pp. 966417. DOI: 10.3389/fimmu.2022.966417
  15. Jayasinghe M., Prathiraja O., Kayani A.M.A., Jena R., Caldera D., Silva M.S., Singhal M., Pierre J. Jr. The Role of Diet and Gut Microbiome in Multiple Sclerosis. Cureus, 2022, vol. 14, no. 9, pp. e28975. DOI: 10.7759/cureus.28975
  16. Yousefi B., Babaeizad A., Banihashemian S.Z., Feyzabadi Z.K., Dadashpour M., Pahlevan D., Ghaffari H., Eslami M. Gastrointestinal Tract, Microbiota and Multiple Sclerosis (MS) and the Link Between Gut Microbiota and CNS. Curr. Microbiol., 2022, vol. 80, no. 1, pp. 38. DOI: 10.1007/s00284-022-03150-7
  17. Miyauchi E., Shimokawa C., Steimle A., Desai M.S., Ohno H. The impact of the gut microbiome on extra-intestinal autoimmune diseases. Nat. Rev. Immunol., 2023, vol. 23, no. 1, pp. 9–23. DOI: 10.1038/s41577-022-00727-y
  18. Garabatos N., Santamaria P. Gut Microbial Antigenic Mimicry in Autoimmunity. Front. Immunol., 2022, vol. 13, pp. 873607. DOI: 10.3389/fimmu.2022.873607
  19. Lin W.-S., Lin S.-J., Liao P.-Y., Suresh D., Hsu T.-R., Wang P.-Y. Role of Ketogenic Diets in Multiple Sclerosis and Related Animal Models: An Updated Review. Adv. Nutr., 2022, vol. 13, no. 5, pp. 2002–2014. DOI: 10.1093/advances/nmac065
Received: 
17.05.2023
Approved: 
13.09.2023
Accepted for publication: 
20.09.2023

You are here

Home